Integrated transcriptome and metabolome analysis of melanin-related genes and metabolites in Muchuan Black Bones Chickens Authors: Liu Wei, Jie Hong-Wei, Gao Ming-Chao, Yao Xiu-Mei, Yin Qiong, Xiang Hai, Ma Zheng, Zhang Zheng-Fen, Li Liang, Li Hua, Qi Hao, Ye Fei, Andre van Wijnen, Andre van Wijnen, Andre van Wijnen, Andre van Wijnen Published: 2025 ABSTRACT The Muchuan Black Bones Chickens represent a significant subtype of the Sichuan mountain black bones chickens. In the breeding of black bone chickens, the degree of melanization tends to separate due to hybridization, while molecular-assisted breeding techniques were still limited, and the key genes involved in melanin deposition in the early growth of black bones chickens have yet to be validated. Hypothesize that melanin deposition in Muchuan Black Bones Chickens was governed by specific genetic and metabolic regulators that can be systematically identified. This study aims to identify key genes and metabolites associated with melanin in Muchuan Black Bones Chickens through integrated transcriptomic and metabolomic analyses. CDP-ethanolamine, m-trigallic acid, UDP-4-dehydro-6-deoxy-D-glucose, glucoiberverin, and uridine diphosphate glucuronic acid (UDP glucuronic acid) were identified as significant differential metabolites, which were intimately linked to phenylalanine, tyrosine, and tryptophan biosynthesis associated with melanin accumulation. A total of 73 differentially expressed genes, including cAMP response element-binding protein 5 (CREB5) and GIPC PDZ domain containing family member 2 (GIPC2), were enriched in the neuroactive ligand-receptor interaction pathway, arginine-proline metabolism pathway, histidine metabolism, terpenoid backbone biosynthesis, and glycerophospholipid metabolism. This study identified significant metabolites and regulatory genes associated with melanin synthesis, establishing a theoretical foundation for the breeding and selection of chickens. Introduction Muchuan Black Bones Chickens, also referred to as “West Sichuan Black Bones Chickens” [1], were renowned for their distinctive black bones and rich nutritional value [2–4]; however, they exhibit segregation in melanin deposition, which emerged in the early stages of growth. Melanin can be divided into five different types: eumelanin, fusomelanin, isomelanin, neuromelanin, and pyomelanin [5]. Black bone chickens primarily consist of eumelanin, a polymer made from 5, 6-dihydroxyindole (DHI) and 5, 6-dihydroxyindole-2-carboxylic acid (DHICA) [6]. The synthesis and transport of melanin were regulated by multiple genes, such as Endothelin Receptor Type B2 (EDNRB2) [7], Endothelin 3 (EDN3) [8], tyrosinase (TYR) [9], tyrosinase-related protein 1 (TYRP1) [10], microphthalmia-associated transcription factor (MITF) [11], and melanosome protein 17 (PMEL17) [12]. EDNRB2, a G protein-coupled receptor, activates downstream signaling pathways upon binding with EDN3, which supports the migration of neural crest-derived melanoblasts to skin and feather regions. The TYR and TYRP1 families formed an enzymatic network for melanin synthesis, where TYR catalyzed the oxidation of tyrosine to dopaquinone, while TYRP1 stabilized TYR enzyme activity, catalyzed the isomerization of dopa pigment, and facilitated deposition onto the melanosome matrix fiber formed by PMEL17. The MLPH gene dynamically regulated melanin from synthesis to distribution, whereas MITF influenced the expression of MLPH and indirectly affected melanin formation. Furthermore, the interaction between MITF and the M-box motif is essential for the coordinated transcriptional regulation of tyrosinase family genes, highlighting the pivotal role of MITF in controlling melanin biosynthesis. Previously, many molecular biological methods studying the melanin deposition included transcriptomic and proteomic [13–14], SNP molecular marker screening [15]. Melanin content was determined using spectrophotometry [16], high-performance liquid chromatography (HPLC) [17], and fluorescence analysis [18], while melanin extraction was achieved through enzymolysis [19], a three-step method (degreasing-enzymolysis-acidolysis) [20]. At the early growth stage of black bones chickens, melanin is deposited in the breast and skin with a marked degree of separation. It is hypothesized that breast muscle melanin deposition in Muchuan Black Bones Chickens is regulated by specific genetic and metabolic factors. To identify candidate molecular markers connected to melanin deposition in the early development phase of Muchuan Black Bones Chickens, this study utilized 35-day-old Muchuan Black Bones Chickens as experimental subjects to identify key genetic markers and metabolites associated with early breast muscle melanin deposition. Materials and methods Sample collection All Muchuan Black Bones Chickens were sourced from Muchuan County Black Phoenix Black Bone Chickens Industry Co., Ltd. The chickens were raised at the Foshan Animal Breeding Engineering Technology Research Center, following standard broiler feeding protocols until 35 days of age. A total of 60 chickens aged 35 days old were selected randomly. Euthanasia was carried out by using the gas fainting method. Gently place the poultry into a sealed chamber, close the lid securely, and gradually introduce CO₂. The initial gas concentration should be maintained at 30% to 50%. Following confirmation of unconsciousness, increase the CO₂ concentration to at least 90%, and continue to maintain this environment for another 5–10 minutes. Once death has been confirmed, proceed with sample collection. Whole blood (2 ml) was collected via wing veins and stored in collection vessels at −20°C for sequencing purposes. Breast muscle was also collected and stored at −80°C for subsequent analysis. Determination of melanin in breast muscle The melanin concentration in the breast muscles was determined through a chicken melanin double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit (manufacturer: Shanghai Enzyme Biotech Co., Ltd.; model: YJ500392) [21]. A total of 0.1 g of breast muscle was homogenized in 900 μL PBS buffer, and the supernatant was collected. Standard wells, blank control wells, and sample wells were assigned on the ELISA plate prior to the assay. Three technical replicates were established for each condition, with corresponding reagents and samples added according to the manufacturer’s instructions. Following incubation and washing steps, a termination solution was added, and the OD value (absorbance) of each well was measured at a wavelength of 450 nm using an ELISA reader, with results recorded within 15 minutes [22]. RNA-seq sequencing Samples were categorized into a high-melanin group (MH) and a low-melanin group (ML) based on the measured melanin content of the breast muscle. Five chickens from each group were selected, and appropriate amounts of breast muscle tissue samples were collected for mRNA transcriptome sequencing. To confirm the reliability of transcriptome sequencing data, the extracted total RNA samples were subjected to rigorous quality control assessments, including purity evaluation, concentration measurement, and integrity verification [23]. The sample concentrations ranged between 420 and 740 ng/μL, with OD 260/280 values [24] approximately around 2.0 by using NanoDrop 2000 spectrophotometer, and all integrity evaluation index RIN values from 7 to 7.6 by using the Agilent 2100/LabChip GX [25]. All total RNAs met quality standards and were suitable for subsequent experimental steps. The library was constructed, including mRNA interruption and enrichment, cDNA purification, end repair, A-tail and splicing connected for sequencing, fragment size selection with AMPure XP beads, and a cDNA library obtained by PCR enrichment. After the library construction, the quality control was performed on the resulting libraries. After passing quality inspection, the transcriptome library was sequenced in PE150 mode using the Illumina NovaSeq 6000 sequencing platform. After the sequencing data were obtained, BMKCloud (https://international.biocloud.net/zh/dashboard) was used to analyze differentially expressed genes through the DESeq2-edgeR methods, with an FDR threshold of 0.05 and a fold change (FC) of 1.5 as the criterion for significance. Differentially expressed genes were analyzed for functional enrichment using the DAVID Bioinformatics Resources database (https://david.ncifcrf.gov/), including pathway enrichment analyses from the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Additionally, Sangerbox 3.0 (http://www.sangerbox.com/) was used to visualize genetic variations via volcano plots and to generate GO and KEGG bubble charts. Assessment via quantitative real-time PCR (RT-qPCR) Reverse transcription was performed with HiScript III All-in-one RT SuperMix (Vazyme, China), yielding cDNA at concentrations≥1 ng/µL. Primer sequences were designed using the NCBI’s Primer–BLAST platform. The primer sequences were shown in Table 1. qPCR was carried out with SYBR Green Master Mix (Vazyme) to determine relative mRNA expression. The Qubit 3.0 (Thermo) fluorometer was used. The results were analyzed based on calculation 2−∆∆Ct. 10.1371/journal.pone.0338827.t001Table 1Differential gene primer sequence.GeneForward primer (5’ → 3’)Reverse primer (5’ → 3’)Annealing temperature (。C)Product size (bp) GAPDH GTAGTGAAGGCTGCTGCTGATGCAAAGGTGGAGGAATGGCTGTC60°C131 TPM2 TGGAACTCCAGGAAATGCAACTATGAGGGATTTGAGGCTCTGGT60°C202 CREB5 CAAAGATGAACTTGGAGCAGGAGAGAAAGCGTGTCGGTGTAGGAG60°C181 GIPC2 TTAGGCTGGAGTGTTTGTTTGGTAGTGGATTGGTGGAGTCTTTAGTCATTTC60°C182 DUSP1 CAAGGGAGGTTACGAAGCGTCCTGGTCGTACAGAGGGGTA60°C181 Differential gene primer sequence. Extraction and detection of metabolites Metabolomic analysis was performed through a standardized protocol involving initial metabolite extraction, instrumental detection, and final metabolite identification and quantification. Firstly, six chickens in the ML group and six chickens in the MH group were selected for metabolite extraction. The metabolite extraction mainly includes the following steps: following the addition of extraction solvent (methanol: acetonitrile: water, 2:2:1) and magnetic beads, samples underwent mechanical grinding, ultrasonic treatment, static centrifugation, and subsequent vacuum drying of the supernatant [26]. Subsequently, the reconstituted extracts were analyzed using an integrated UPLC-QTOF-MS system (Waters Acquity I-Class PLUS coupled with Waters Xevo G2-XS QTof). The column used is purchased from Waters Acquity UPLC HSS T3 column (1.8um 2.1*100 mm). The collision energy was set to 2V for low energy and ranged from 10 to 40V for high energy. The scanning frequency was 0.2 seconds per mass spectrum, with a full scan range of m/z 50–1200. The capillary voltage was maintained at 2500V in positive ion mode and -2000V in negative ion mode. The gradient elution procedure was detailed in Table 2. For both positive and negative ion modes, mobile phase A consisted of a 0.1% formic acid aqueous solution, and mobile phase B consisted of 0.1% formic acid acetonitrile. Injection volume 1 µL. Chromatographic separation and mass spectrometric detection were performed under optimized analytical conditions. Acquired data (MassLynx V4.2) were processed through Progenesis QI software for feature extraction, peak alignment, and data normalization. Metabolite identification was achieved by cross-referencing with the METLIN database, public repositories, and a custom-established Baimaike database, complemented by theoretical fragmentation pattern analysis. Mass accuracy thresholds were maintained at 100 ppm for precursor ions and 50 ppm for product ions. The PCA analysis and orthogonal partial least squares discriminant analysis (OPLS-DA) were conducted using the BMKCloud (https://international.biocloud.net/zh/dashboard). Differential metabolite screening was performed based on multivariate and univariate statistical analyses. The Variable Importance in Projection (VIP) values derived from the OPLS-DA model were initially employed to identify potential metabolic differences between cultivars or tissues. Subsequently, these findings were integrated with univariate analysis results to enhance the reliability of differential metabolite selection. The screening criteria were set at FC > 1, P < 0.05, and VIP > 1. The final results were visualized using a volcano plot. The cluster profile package was employed to perform an enrichment analysis of KEGG annotation results using the hypergeometric test, and an enrichment dot plot was created. 10.1371/journal.pone.0338827.t002Table 2Gradient elution program used for chromatographic separation.Time (min)Flow rate (μL/min)Mobile phase A (%)Mobile phase B (%)0.04009820.2540098210.040029813.040029813.140098215.0400982(1) Mobile phase A: 0.1% formic acid aqueous solution.(2) Mobile phase B: 0.1% formic acid acetonitrile. Gradient elution program used for chromatographic separation. (1) Mobile phase A: 0.1% formic acid aqueous solution. (2) Mobile phase B: 0.1% formic acid acetonitrile. Integrative investigation of transcriptional and metabolic networks Comprehensive bioinformatics analysis of gene expression and metabolic profiles was carried out utilizing the BMK Cloud analytical suite (www.biocloud.net), including library quality assessment, principal component analysis, differential expression analysis, gene function and metabolic pathway annotation and functional enrichment, and combined analysis. Weighted gene co-expression network analysis (WGCNA) was performed using the BMK Cloud analytical suite (www.biocloud.net) following the standard workflow. Based on transcriptome and metabolome data obtained from the platform’s early-stage analysis, the differential expression analysis was performed using DESeq2_EBSeq with an FDR threshold of 0.05 and a fold change cutoff of 1.5. Analyze according to the previous groupings of MH and ML. Results Comparison of melanin content in breast muscle A comparison of high and low levels of melanogenesis and subsequent deposition in the breast muscle of Muchuan Black Bones Chickens was shown in Fig 1(A). As illustrated in Fig 1(B), black bones chickens were selected for the ML group (low melanin expression group) and the MH group (high melanin expression group) based on their melanin content; the expression levels of melanin in breast muscle were (103.193 ± 3.598) mg/mL and (121.731 ± 3.69) mg/mL, respectively. Statistical analysis revealed a significantly elevated melanin concentration in the pectoral muscle tissue of the high-level group compared with the low-level group (P < 0.01). The results of phenotype of Muchuan black bones chickens and the expression of genes. (A) Comparison of blackness between MH and ML black bones chickens. (B) Statistical significance of melanin content. ** was meant the extremely significant. (C) DEGs volcano map. (D) Expression trend of differential gene transcriptome sequencing and real-time fluorescence quantitative PCR of GIPC2. (E) Expression trend of differential gene transcriptome sequencing and real-time fluorescence quantitative PCR of CREB5. (F) The transcriptome sequencing results of the GIPC gene family and the CREB gene family. Transcriptome analysis Raw sequencing data quality assessment summary. Table 3 present a summary of the RNA-Seq results of Muchuan Black Bones chicken breast samples, comprising five ML and five MH samples, along with both raw and clean reads. The Q30 value exceeded 90.43%, and the Q20 value exceeded 96.11%, while the GC content ranged from 52.36% to 53.38%. 10.1371/journal.pone.0338827.t003Table 3Summary statistics of sequence quality and comparison information.SamplesClean readsClean basesGC Content% ≥ Q30% ≥ Q20ML120,315,2076,078,541,55252.83%91.26%96.61%ML221,641,1486,474,947,59053.05%91.99%96.89%ML323,440,9777,011,163,86252.42%92.62%97.17%ML419,689,0635,890,581,03852.93%91.99%96.89%ML521,212,5906,345,204,43052.77%92.00%96.88%MH122,064,7816,598,044,17453.38%94.93%98.01%MH222,248,2606,656,734,11452.36%92.98%97.33%MH322,280,8886,665,761,31652.64%92.48%97.15%MH421,542,5996,445,733,21452.96%90.43%96.11%MH520,685,5516,187,410,71052.37%91.56%96.70%(1) Samples: sample analysis number.(2) Clean reads: Total paired-end reads post-quality filtration.(3) Clean bases: Clean Data total bases.(4) GC content: GC composition ratio in quality-filtered sequencing data.(5) ≥Q30%: Percentage of high-quality bases (Q ≥ 30) in processed sequencing reads.(6) ≥Q20%: Percentage of high-quality bases (Q ≥ 20) in processed sequencing reads. Summary statistics of sequence quality and comparison information. (1) Samples: sample analysis number. (2) Clean reads: Total paired-end reads post-quality filtration. (3) Clean bases: Clean Data total bases. (4) GC content: GC composition ratio in quality-filtered sequencing data. (5) ≥Q30%: Percentage of high-quality bases (Q ≥ 30) in processed sequencing reads. (6) ≥Q20%: Percentage of high-quality bases (Q ≥ 20) in processed sequencing reads. Gene differential expression analysis. Transcriptomic analysis revealed significant differential gene expression patterns between high and low melanin groups, identifying 73 DEGs (54 up-regulated and 19 down-regulated), as illustrated in Fig 1(C). The top ten DEGs based on log2(FC) were presented in Table 4. 10.1371/journal.pone.0338827.t004Table 4The top ten genes that differential expressed.GeneFull namelog2(FC)UP/DOWN MHM2 male hypermethylated region 23.03UP KCNK3 Potassium Two Pore Domain Channel Subfamily K Member 32.08UP ITGB6 integrin subunit beta 62.15UP TET2 Ten-Eleven Translocation 22.25UP GIPC2 GIPC PDZ domain-containing family member 22.58UP MYOZ2 Myozenin 22UP CREB5 cAMP-responsive element-binding protein 51.37UP TMEM8C Transmembrane Protein 8C1.01UP TRPC3 Transient Receptor Potential Canonical 3−2.24DOWN ATP6V1G3 ATPase H+ transporting V1 subunit G3−2.1DOWN The top ten genes that differential expressed. Data quality assessment of RT-qPCR. The expression patterns of the two differentially expressed genes, validated by both transcriptome sequencing and RT-qPCR, were presented. The figure shown that the RNA-seq expression level of the GIPC2 gene in the MH group was approximately 5-fold higher than that in the ML group, while the RT-qPCR expression level in the MH group was 4.5-fold higher in Fig 1(D). Similarly, for the CREB5 gene (Fig 1(E)), the RNA-seq expression level in the MH group was 5-fold higher compared to the ML group, and the RT-qPCR expression level was 3.1-fold higher. These results were demonstrated a largely consistent expression pattern between the two methods. The transcriptional profiles of the CREB and the GIPC gene families obtained from RNA sequencing were presented in Fig 1(F). Transcriptome sequencing results revealed that, apart from the previously identified members, other CREB family members in the MH group did not exhibit consistent up-regulation. Within the GIPC family, GIPC2 expression was elevated in the MH group compared to the ML group, whereas GIPC1 expression levels remained comparable between the two groups. GO enrichment analysis of DEGs. The classification of differentially expressed genes (DEGs) from the high and low melanin content groups into GO terms were revealed significant enrichment (P < 0.05) across 6 functional categories. Biological processes (BP) were included auditory receptor cell stereocilium organization and axon development. Cellular components (CC) were encompassed dendrites, integral plasma membrane components, and plasma membranes. Molecular functions (MF) were characterized by integrin binding, as illustrated in Fig 2(A). Enrichment analysis of DEGs. (A) Functional enrichment of DEGs GO. (B) Enrichment of DEGs KEGG pathway. KEGG enrichment analysis of DEGs. The KEGG pathway enrichment analysis was identified two metabolic pathways with significant enrichment (P < 0.05). The neuroactive ligand-receptor interaction pathway may regulate melanocyte activity via neuroendocrine signals, such as α-MSH/MC1R, thereby modulating melanin deposition in the pectoral muscles. The arginine-proline metabolism pathway may influence melanin production by supplying amino acid precursors and supporting the metabolic environment required for melanin synthesis, as demonstrated in Fig 2(B). Pathways associated with pigmentation were included adrenergic signaling in cardiomyocytes, the calcium signaling pathway, and the mitogen-activated protein kinase (MAPK) signaling pathway. Based on the enrichment results from both GO and KEGG, the adrenergic signaling pathway in cardiomyocytes included the tropomyosin 2 (TPM2) gene (log2(FC)=2.67) and cAMP-responsive element binding protein 5 (CREB5) gene (log2(FC)=1.37); the calcium signaling pathway included histamine receptor H2 (HRH2) gene (log2(FC)=1.09) and fibroblast growth factor 1 (FGF1) gene (log2(FC)=0.06); while the MAPK signaling pathway included dual specificity phosphatase 1 (DUSP1) gene (log2(FC)=0.34) and fibroblast growth factor 1 (FGF1) gene (log2(FC)=0.06). Differential gene expression ratios and regulation were shown in Table 5. 10.1371/journal.pone.0338827.t005Table 5The differentially expressed genes enriched by KEGG.Gene IDFull namelog2(FC)UP/DOWN TPM2 tropomyosin 22.67Up CREB5 cAMP responsive element binding protein 51.37Up HRH2 histamine receptor H21.09Up FGF1 fibroblast growth factor 10.06Up DUSP1 dual specificity phosphatase 10.34Up The differentially expressed genes enriched by KEGG. Metabolome analysis PCA analysis. The distribution of samples along PC1 and PC2 was illustrated in Fig 3, from which it was inferred that the MH and ML groups exhibited significant differences in metabolic composition. PCA analysis of all samples in two dimensions. OPLS-DA analysis. To enhance the identification of differential metabolites, this study also performed orthogonal partial least squares discriminant analysis (OPLS-DA). As illustrated in Fig 4(A), samples from the MH and ML groups were distinctly separable along the t1 axis. To mitigate overfitting, the model was verified in this experiment, as shown in Fig 4(B). The figure demonstrates that R2Y values predominantly cluster around 1, indicating that the model was robust and not subject to overfitting. OPLS-DA analysis of differential metabolites. (A) Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA). (B) OPLS-DA model replacement test diagram. Differential metabolite analysis. The metabolomic screening identified 234 differentially abundant metabolites, among which 158 were significantly down-regulated and 76 were up-regulated, as shown in Fig 5(A). Among the down-regulated metabolites highlighted, several notable compounds include products associated with sugar metabolism, included uridine diphosphate glucuronic acid (UDP-glucuronic acid) and UDP-4-dehydro-6-deoxy-D-glucose. Compounds involved in the phospholipid synthesis pathway included CDP-ethanolamine. Metabolites related to redox and signal regulation included methyl gallate and glucose isoflavone. The volcanic map of differential metabolites and KEGG enrichment map of differential metabolites. (A) Volcanic map of differential metabolites. (B) KEGG enrichment map of differential metabolites. KEGG enrichment analysis of differential metabolites. Significant enrichment of histidine metabolism, terpenoid backbone biosynthesis, and glycerophospholipid metabolism pathways was observed, as shown in Fig 5(B). The process of melanin synthesis was accompanied by the production of reactive oxygen species (ROS). The enhanced metabolism of histidine [27,28]. Terpenoid backbone biosynthesis provides the isoprenoid precursors required for the synthesis of ubiquinone (coenzyme Q), a key antioxidant molecule that participates in maintaining redox homeostasis during melanogenesis [29,30]. Integrated transcriptome and metabolome analysis Weighted gene co-expression network analysis (WGCNA). This study conducted WGCNA analysis on the transcriptome and metabolome data independently, revealing that certain modules, such as MEdarkmagenta and GEmagenta, exhibited strong positive correlations in the heatmap, as shown in Fig 6 Conversely, a strong negative correlation was observed between MElightyellow and GEdarkgreen. Weighted gene Co-expression network analysis (WGCNA). Bidirectional orthogonal partial least squares analysis. Joint Score 1 accounts for the maximum shared variation between transcriptomic and metabolomic data, whereas Joint Score 2 captures the secondary shared variation. The distribution of W8 (red) was relatively close to that of B8 (blue), as illustrated in Fig 7(A). Bidirectional orthogonal partial least squares analysis. (A) ML vs MH O2PLS scores. (B) ML vs MH top15 O2PLS loadings bar. Based on the results of element loading values, this study identified the top 15 differential genes and metabolites with the highest loading values in the first two principal components and constructed bar charts to illustrate those with the strongest associations, as shown in Fig 7(B), genes exhibiting significant upregulation, such as TANGO2 (transport and golgi organization 2 homolog) and NewGene_4870, were listed, along with genes showing significant downregulation, included CD63 (CD63 molecule) and LARP6 (La ribonucleoprotein 6, translational regulator); genes such as TPM2, CREB5, HRH5, FGF1, and DUSP1, the expression levels of these genes were relatively low, as indicated by their small loading values (|Loading1| < 0.01 and |Loading2| < 0.01). Specific compounds, such as Semivioxanthin and Gossypol, demonstrate significant positive or negative loading values within the model, highlighting their crucial roles in metabolomic data. Discussion The deposition of melanin in Muchuan Black Bones chickens has a pronounced impact on appearance quality, and higher levels of melanin are positively associated with improved nutritional value [31]. Although progress has been made in breeding research on Muchuan Black Bones Chickens in recent years, most existing studies have primarily focused on selecting for black skin traits, emphasizing external appearance and market value. In contrast, research on melanin deposition in the breast muscle remains limited, and available data are largely derived from older birds [32]. Consequently, the specific influence of breast muscle melanin deposition on appearance-related traits—particularly its regulatory mechanisms across different growth stages—remains insufficiently explored. Through the previous observation, it was found that the melanin deposition in the early growth stage (35 days of age) had shown a significant degree of separation, especially in the breast muscle and skin [33]. These findings highlight the necessity of further investigation into early-stage melanin deposition, with particular emphasis on developing breeding strategies that could optimize its contribution to appearance quality. The transcriptomic analysis revealed that two genes associated with melanin synthesis, namely GIPC2 and CREB5, were significantly up-regulated. Previous studies have demonstrated that the missense mutations D125N and E288K in GIPC2 were implicated in malignant melanoma development [34]. As a transcription factor belonging to the CREB family, CREB5 exerts its regulatory function by specifically interacting with cAMP response elements (CREs) in downstream genes [35], thereby playing a regulatory role in various cell-specific biological activities, including cell growth, survival, metabolism, and differentiation. It has been established that members of the CREB family can enhance melanogenesis through microphthalmia-associated transcription factor (MITF) activation; however, the specific role of CREB5 in this context remains inadequately characterized. As an integral component of the CREB family, CREB5 may indirectly influence MITF expression via analogous mechanisms [11]. A critical regulatory pathway for melanogenesis was the cAMP response elements (cAMP-PKA) signaling cascade, which can be further modulated by activating CREB family transcription factors. Consequently, CREB5 may play a significant role in this pathway and impact the expression of downstream genes associated with melanogenesis. The RNA-seq results suggest that transcript-level compensation of CREB5 by other CREB family members was minimal or absent. Although some family members were highly expressed, they did not display a uniform inverse pattern relative to CREB5 that would support compensatory transcriptional responses. Although GIPC2 exhibited an up-regulated trend in the MH group, no corresponding inverse expression pattern or negative correlation was observed with other family members. Therefore, current evidence supports only a potential transcriptional-level response for GIPC2, rather than confirming a definitive gene or messenger ribonucleic acid (mRNA) compensatory effect. In the GO enrichment analysis, integrins were critical adhesion receptors that regulate cell migration and attachment to the extracellular matrix. During development, melanocytes are migrate from the neural crest and successfully colonize target tissues such as the dermis or skeletal muscle [36]. The presence of this pathway suggest that integrin-mediated adhesion may facilitate melanocyte migration and anchoring within the pectoral muscle of Muchuan black-bone chickens, thereby promoting stable melanocyte settlement and subsequent melanin deposition. In the KEGG enrichment pathways, the enrichment of the neuroactive ligand-receptor interaction pathway was highly consistent with the regulatory mechanisms of melanogenesis. Melanin production in melanocytes was under neuroendocrine control, and a well-known example was the melanocortin 1 receptor (MC1R), a neuroendocrine receptor activated by ligands such as α-MSH. MC1R signaling initiates the cAMP pathway, thereby promoting eumelanin synthesis [37]. The enrichment of this pathway in Muchuan black-bone chickens, therefore, highlights the plausible involvement of neuroendocrine factors in the regulation of melanin deposition in skeletal muscle. The arginine–glutamate metabolism pathway provides metabolic energy and biosynthetic precursors to support melanocyte activity [38]. Moreover, this pathway cooperates with oncogenic signals such as BRAF to drive metabolic reprogramming in melanocytes [39]. Importantly, targeting key enzymes within this pathway, for example, glutaminase inhibition, has been shown to reduce melanin production and suppress melanoma progression, underscoring its dual role in pigment regulation and tumor biology [40]. In the differential metabolite analysis, this study identified Glucoiberverin and Uridine diphosphate glucuronic acid (UDP glucuronic acid) as key metabolites that were significantly associated with melanin deposition. These metabolites were primarily linked to cellular metabolism, which played a crucial role in regulating various biochemical processes that could influence melanin accumulation. Glucoiberin was a natural sulfur-containing glucosinolate that could be enzymatically hydrolyzed into sulforaphane, a compound known to reduce cell viability and modulate the expression levels of various histone deacetylases. Through this mechanism, sulforaphane regulates the acetylation and methylation of specific lysine residues on histones H3 and H4 in malignant melanoma cells [41]. While neither Glucoiberverin nor UDP-glucuronic acid played a crucial role in key melanogenic processes, particularly in facilitating the bioconversion of tyrosine to melanin pigments, their contributions to cellular energy metabolism and metabolic regulation were vital for the overall process of melanin deposition. UDP-glucuronic acid was a key player in glycosylation reactions, particularly in the biosynthesis of glycosaminoglycans and the detoxification processes within the cell [42]. This metabolite facilitated the conjugation of various compounds, enhancing their solubility and excretion, and thereby indirectly influencing cellular function. Its role in glycosylation also extended to the modification of proteins and lipids that may be involved in the regulation of melanin-producing enzymes or the structural integrity of melanocytes. UDP-glucuronic acid may influence the glycosylation of melanogenic enzymes or cellular receptors, thereby affecting the efficiency and regulation of melanin synthesis and ultimately modulating melanin deposition in tissues [43]. Although these metabolites do not directly participate in the melanogenic biochemical pathway, they play pivotal roles in modulating cellular homeostasis, maintaining energy metabolism, and regulating protein post-translational modifications, thereby exerting a substantial influence on melanin deposition processes. This finding highlight the important role of metabolic intermediates in regulating pigment biosynthesis and offered new avenues for exploring the complex interactions between metabolic networks and phenotypic pigmentation, particularly in economically important poultry such as Muchuan Black Bones chickens. These indirect roles may also offer insights into improving the nutritional value and quality of appearance based on melanin content. In addition, differential metabolomic analysis revealed significant enrichment of metabolites such as CDP-ethanolamine, m-trigallic acid, and UDP-4-dehydro-6-deoxy-D-glucose. CDP-ethanolamine (cytidine diphosphate ethanolamine) was a key intermediate in the Kennedy pathway, which was primarily involved in the biosynthesis of phosphatidylethanolamine (PE) [44]. Membrane fluidity was crucial in the process of melanosome formation: it promoted membrane bending and vesicle formation, influenced the localization and function of membrane proteins, and maintained material transport between organelles, thereby ensuring the normal maturation of melanosomes and melanin synthesis. CDP-ethanolamine, as a precursor for PE synthesis, indirectly affected membrane fluidity by regulating PE levels, and its abnormality might have been related to pigmentation disorders. Information on m-trigallic acid was currently limited, and its biological role remains unclear, necessitating further investigation to determine its potential physiological significance in animal systems. UDP-4-dehydro-6-deoxy-D-glucose was a sugar-nucleotide intermediate involved in the biosynthesis of deoxy sugars in microorganisms and plants. Although its function in animals was not well characterized, its enrichment in this study suggests potential metabolic relevance. However, their significant differential abundance in this study suggest they may participate in melanin-related metabolic regulation, warranting further mechanistic investigation. According to the metabolomics, the KEGG was analyzed for two pathways: phenylalanine, tyrosine, and tryptophan biosynthesis. Phenylalanine was enzymatically converted to tyrosine by phenylalanine hydroxylase (PAH), after which tyrosine undergoes further oxidation to form dihydroxyphenylalanine (DOPA) through the action of tyrosinase [45]. Subsequently, DOPA was transformed into dopachrome via a series of intricate chemical reactions, ultimately yielding eumelanin or pheomelanin, which represent the primary types of melanin [46]. A substantial number of studies have identified key genes involved in melanin biosynthesis and pigmentation regulation, often referred to as “marker genes” in melanogenesis. These included EDNRB2, EDN3, TYR, TYRP1, MITF, and PMEL17, which played crucial roles in different stages of melanogenesis, ranging from melanoblast migration to enzymatic catalysis and melanosome formation. However, these genes were not detected in this study due to sequencing limitations; thus, low-expressed genes might not have been effectively captured. Additionally, external factors such as diet, light exposure, and temperature could have influenced melanin production, leading to changes in gene expression patterns. Although no typical genes regulating melanin were detected, this method identified new regulatory factors beyond the core pathway, such as CERB5, GIPC2, etc. Conclusion This study identified that the GIPC2 and CREB5 genes were associated with melanin deposition. In parallel, several metabolites, including CDP-ethanolamine, m-trigallic acid, UDP-4-dehydro-6-deoxy-D-glucose, and UDP-glucuronic acid, were found to be significantly associated with pigmentation. These findings not only provided candidate targets for future multi-omics studies (e.g., epigenomics, proteomics) to unravel the regulatory mechanisms of pigmentation but also offered potential biomarkers for selective breeding in black-bone chickens. 3 Sep 2025 Dear Dr. Fei, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: Thank you for submitting your manuscript to PLOS ONE. We were able to secure only one reviewer for your paper, even though we invited many experts on behalf of your paper. After careful editorial consideration, and in view of the comments of the reviewer, we feel that your paper has merit but requires revision. Therefore, we invite you to submit a revised version of the manuscript that addresses comprehensively addresses the points of both the reviewer and the editor. ============================== Please submit your revised manuscript by Oct 18 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Andre van Wijnen Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. 3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 4. Thank you for stating the following financial disclosure: [This research was funded by the Guangdong Basic and Applied Basic Research Foundation (2022A1515111078) and Guizhou Science and Technology Key Project ([2022] No. 034).]. Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 5. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 6. Thank you for stating the following in the Competing Interests section: [Guangdong Tinoo’s Food Co., Ltd]. We note that one or more of the authors are employed by a commercial company: name of commercial company. 1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. 2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: ""This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. 7. Please include a caption for figure 1 to 6 and table 1 and 2. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: Editorial Comments: Please present Figure 1D with the same level of data transparency as Figure 1B. In addition, expand figure 1D by presentation of RNA-seq data for other CREB members (e.g., CREB1/2/3/4) and GIPC members (e.g., GIPC1, GIPC3) to assess whether there is the possibility for gene/mRNA compensation. Reviewer #1: [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Reviewer #1: This manuscript employs a multi-omics approach (transcriptomics and metabolomics) to investigate the molecular basis of variable melanin deposition in the breast muscle of 35-day-old Muchuan Black-Bone chickens. The study identifies novel candidate genes (CREB5, GIPC2) and metabolites beyond the well-characterized melanogenic pathway, providing new insights into a commercially important trait. However, the manuscript requires significant revisions to: Abstract Discrepancy: A critical inconsistency exists where the abstract highlights "Glucose-6-phosphate" as a key metabolite, but this compound is absent from the main results and discussion, which focus on entirely different metabolites (e.g., CDP-ethanolamine, UDP-glucuronic acid). This must be corrected for accuracy. Superficial Interpretation of Pathways: The authors list enriched pathways (e.g., Arginine-Proline metabolism, Histidine metabolism) but do not adequately discuss their plausible biological connection to melanogenesis. The manuscript would be significantly strengthened by deeper mechanistic hypothesizing. Insufficient Methodological Detail: Key details are missing from the methods section, preventing full reproducibility. Most critically, the qPCR primer sequences and reference genes are omitted. The metabolomics extraction solvent and chromatography conditions are also not specified. Underdeveloped Integration: While both omics datasets are presented, their true integration is limited to showing correlations between modules (WGCNA) and joint variation (O2PLS). The most valuable step—directly correlating key DEGs with key metabolites to generate testable hypotheses—is missing. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. Submitted filename: PONE-D-25-36595.pdf 26 Oct 2025 Additional Editor Comments: Editorial Comments: Please present Figure 1D with the same level of data transparency as Figure 1B. In addition, expand figure 1D by presentation of RNA-seq data for other CREB members (e.g., CREB1/2/3/4) and GIPC members (e.g., GIPC1, GIPC3) to assess whether there is the possibility for gene/mRNA compensation. Reviewer #1:Regarding the issues raised by the journal editors, corresponding changes have been made in the revised version of the article (the changed parts are highlighted in yellow) and in Fig1(D). Submitted filename: Response Letter#.docx 9 Nov 2025 Dear Dr. Fei, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 24 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Andre van Wijnen Academic Editor PLOS ONE Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Editorial Comments: This paper is acceptable for publication pending final revisions that address minor comments. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Reviewer #1: The manuscript presents a well-designed multi-omics study that "Integrated Transcriptome and Metabolome Analysis of Melanin-related genes and Metabolites in Muchuan Black Bones Chickens". The identification of novel candidate genes, and metabolites is a valuable contribution to the field. The revisions made in response to the previous editorial and reviewer comments have significantly improved the manuscript's clarity and depth. However, several issues, primarily concerning language, clarity, and data interpretation, still need to be addressed before the manuscript is suitable for publication. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Owais Iqbal ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 20 Nov 2025 Dear Editor, We would like to sincerely thank you and the reviewers for the time and effort you have devoted to evaluating our manuscript entitled "Transcriptome and Metabolome Combined to Analyze the Key Genes and Metabolites Related to the Melanin Content of Muchuan Black Bones Chickens" (Manuscript ID:PONE-D-25-36595). We greatly appreciate the constructive comments and valuable suggestions, which have helped us to improve the quality of our work. We have carefully revised the manuscript according to the reviewers’ comments. Below, we provide a detailed point-by-point response to each comment. Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Response:We reviewed all cited references using the Retraction Watch Database, and no retracted publications were identified. The manuscript presents a well-designed multi-omics study that "Integrated Transcriptome and Metabolome Analysis of Melanin-related genes and Metabolites in Muchuan Black Bones Chickens". The identification of novel candidate genes, and metabolites is a valuable contribution to the field. The revisions made in response to the previous editorial and reviewer comments have significantly improved the manuscript's clarity and depth. However, several issues, primarily concerning language, clarity, and data interpretation, still need to be addressed before the manuscript is suitable for publication. Response:We made revisions to the manuscript, improving the language expression, enhancing the clarity of the charts, and modifying the image sizes, in an effort to meet the requirements of the journal. However, changing the size of the image may affect some clarity. Sincerely, YE Fei Foshan University 2025/11/19 Submitted filename: Response Letter-2.docx 28 Nov 2025 Integrated Transcriptome and Metabolome Analysis of Melanin-related genes and Metabolites in Muchuan Black Bones Chickens PONE-D-25-36595R2 Dear Dr. Fei, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Andre van Wijnen Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Reviewer #1: There are some spelling, space and formatting issues in the manuscript. Please check and revised carefully ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Owais Iqbal ********** PONE-D-25-36595R2 PLOS One Dear Dr. Fei, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Andre van Wijnen Academic Editor PLOS One